St Jude Medical's Angio-Seal STS Plus vascular closure device
This article was originally published in Clinica
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for the Angio-Seal STS Plus vascular closure device, a product developed by St Jude Medical to help seal catheterisation sites. It is approved for both percutaneous peripheral and cardiac interventional catheterisation procedures, and enables physicians to seal the femoral artery punctures made during the surgery. The device incorporates a self-tightening suture, which St Paul, Minnesota-based St Jude claims is a significant advantage over its Angio-Seal Millennium vascular closure platform, which has been used in Japanese cath labs since 2004. The Ministry has also granted reimbursement approval for the device.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.